Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Ilaria Dando

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6390-4184; OpenAlex author ID A5014448714. Sources: OpenAlex.

Their work

Papers
22 (first author 5, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
40
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 5 papers · 2014: none · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 22

  1. TRAP1 ablation improves mitochondrial cristae and oxidative phosphorylation in pancreatic cancer stem cells. Last author DOI 10.20517/cdr.2025.229↗
  2. New Insights into Metabolic Alterations and Mitochondria Re-Arrangements in Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers15153906↗
  3. Divergent Roles of Mitochondria Dynamics in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers14092155↗
  4. 3-Bromo-Isoxazoline Derivatives Inhibit GAPDH Enzyme in PDAC Cells Triggering Autophagy and Apoptotic Cell Death. Co-author DOI 10.3390/cancers14133153↗
  5. Mitochondrial Elongation and OPA1 Play Crucial Roles during the Stemness Acquisition Process in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers14143432↗
  6. Integrated lipidomics and proteomics reveal cardiolipin alterations, upregulation of HADHA and long chain fatty acids in pancreatic cancer stem cells. Co-author DOI 10.1038/s41598-021-92752-5↗
  7. Progressively De-Differentiated Pancreatic Cancer Cells Shift from Glycolysis to Oxidative Metabolism and Gain a Quiescent Stem State. Last author DOI 10.3390/cells9071572↗
  8. Extracellular Matrix Composition Modulates the Responsiveness of Differentiated and Stem Pancreatic Cancer Cells to Lipophilic Derivate of Gemcitabine. Co-author DOI 10.3390/ijms22010029↗
  9. Pancreatic cancer stem cell proliferation is strongly inhibited by diethyldithiocarbamate-copper complex loaded into hyaluronic acid decorated liposomes. Co-author DOI 10.1016/j.bbagen.2018.09.018↗
  10. Extracellular matrix composition modulates PDAC parenchymal and stem cell plasticity and behavior through the secretome. Co-author DOI 10.1111/febs.14471↗
  11. Proteomic analysis of pancreatic cancer stem cells: Functional role of fatty acid synthesis and mevalonate pathways. First author DOI 10.1016/j.jprot.2016.10.002↗
  12. Secretome protein signature of human pancreatic cancer stem-like cells. Co-author DOI 10.1016/j.jprot.2016.01.017↗
  13. Mitochondrial uncoupling protein 2 and pancreatic cancer: a new potential target therapy. First author DOI 10.3748/wjg.v21.i11.3232↗
  14. Pancreatic ductal adenocarcinoma cell lines display a plastic ability to bi‑directionally convert into cancer stem cells. First author DOI 10.3892/ijo.2014.2796↗
  15. Comparative proteomic and phosphoproteomic profiling of pancreatic adenocarcinoma cells treated with CB1 or CB2 agonists. First author DOI 10.1002/elps.201200402↗
  16. Autophagy induced by p53-reactivating molecules protects pancreatic cancer cells from apoptosis. Co-author DOI 10.1007/s10495-012-0790-6↗
  17. UCP2 inhibition triggers ROS-dependent nuclear translocation of GAPDH and autophagic cell death in pancreatic adenocarcinoma cells. Co-author DOI 10.1016/j.bbamcr.2012.10.028↗
  18. Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity. Co-author DOI 10.1016/j.bbamem.2013.01.020↗
  19. Cannabinoids inhibit energetic metabolism and induce AMPK-dependent autophagy in pancreatic cancer cells. Co-author DOI 10.1038/cddis.2013.151↗
  20. Expression of the antiapoptotic protein BAG3 is a feature of pancreatic adenocarcinoma and its overexpression is associated with poorer survival. Co-author DOI 10.1016/j.ajpath.2012.07.016↗
  21. Gemcitabine response in pancreatic adenocarcinoma cells is synergistically enhanced by dithiocarbamate derivatives. Co-author DOI 10.1016/j.freeradbiomed.2011.01.001↗
  22. Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. First author DOI 10.1038/cddis.2011.36↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elisa Dalla Pozza · 21 shared papers, 2011–2026 · strength 2.10
  2. Marta Palmieri · 18 shared papers, 2011–2022 · strength 1.13
  3. Giulia Ambrosini · 5 shared papers, 2020–2026 · strength 0.84
  4. Massimo Donadelli · 11 shared papers, 2011–2022 · strength 0.57
  5. Cristian Andres Carmona‐Carmona · 4 shared papers, 2020–2022 · strength 0.55
  6. Daniela Cecconi · 6 shared papers, 2013–2021 · strength 0.42
  7. Jessica Brandi · 6 shared papers, 2013–2021 · strength 0.42
  8. Stefania Forciniti · 4 shared papers, 2018–2022 · strength 0.39
  9. Aldo Scarpa Scarpa · 7 shared papers, 2011–2017 · strength 0.26
  10. Silvia Arpicco · 4 shared papers, 2011–2020 · strength 0.24
  11. Raffaella Pacchiana · 2 shared papers, 2020–2022 · strength 0.23
  12. Giulia Biondani · 4 shared papers, 2015–2018 · strength 0.23
  13. Claudia Di Carlo · 2 shared papers, 2020–2021 · strength 0.22
  14. Emílio Marengo · 2 shared papers, 2016–2021 · strength 0.18
  15. Maria Raffaella Greco · 2 shared papers, 2018–2020 · strength 0.17
  16. Stephan J. Reshkin · 2 shared papers, 2018–2020 · strength 0.17
  17. Rosa Angela Cardone · 2 shared papers, 2018–2020 · strength 0.17
  18. Paola Conti · 1 shared paper, 2022 · strength 0.14
  19. Eithne Costello · 2 shared papers, 2016–2017 · strength 0.11
  20. Tiago M. A. Carvalho · 1 shared paper, 2020 · strength 0.09
  21. Alessandro Marengo · 1 shared paper, 2019 · strength 0.09
  22. Christopher Heeschen · 1 shared paper, 2019 · strength 0.09
  23. Claudia Fiorini · 2 shared papers, 2013 · strength 0.08
  24. Stefania Cannone · 1 shared paper, 2018 · strength 0.07
  25. Katrine Zeeberg · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.